Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.42 |
| ▸ | CTSA | P10619 | 4/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | UGCG | Q16739 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505072 | 0.87 | ROCK2 (0.40) | ROCK2ROCK1TP53MAPT | |
| SCHEMBL6503078 | 0.80 | ROCK2 (0.40) | ROCK2ROCK1ALOX15MAPT | |
| SCHEMBL6503948 | 0.80 | ROCK2 (0.40) | ROCK2ROCK1ALOX15MAPT | |
| SCHEMBL6496206 | 0.80 | TLR8 (0.35) | ALOX15MAPT | |
| SCHEMBL6495430 | 0.76 | KMT2A (0.44) | ROCK2ROCK1ALOX15TP53MAPT | |
| SCHEMBL6502531 | 0.76 | MEN1 (0.40) | MAPT | |
| SCHEMBL6493590 | 0.74 | LMNA (0.42) | TP53MAPT | |
| Hydrochloric Acid SCHEMBL6494612 | 0.74 | LMNA (0.41) | TP53MAPT | |
| SCHEMBL6494231 | 0.67 | ALOX15 (0.36) | ALOX15TP53MAPT | |
| SCHEMBL6501121 | 0.67 | LTB4R (0.37) | ALOX15TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | claimed |
| US-6858739-B2 | Indole and benzimidazole 15-lipoxygenase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | ALOX15, ALOX5, ALOX12 | ROCK2 1398/4885ROCK1 1364/4885CTSA 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.